6月21日,诺和诺德公司发布减肥药Amycretin早期试验数据。结果显示,在36周内,受试者平均体重下降24.3%,同时药物还显示出改善血糖水平的潜力。这一进展可能为肥胖及糖尿病患者提供新治疗选择。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.